Proactive Pharmaceutical Care Interventions Improve Patients' Adherence to Lipid-Lowering Medication

被引:28
|
作者
Stuurman-Bieze, Ada G. G. [1 ,2 ]
Hiddink, Eric G. [2 ,3 ]
van Boven, Job F. M. [3 ]
Vegter, Stefan [3 ]
机构
[1] West Pharm, NL-8302 NC Emmeloord, Netherlands
[2] Hlth Base Fdn, Houten, Netherlands
[3] Univ Groningen, Dept Pharm, Unit PharmacoEpidemiol & PharmacoEcon, NL-9700 AB Groningen, Netherlands
关键词
adherence; discontinuation; lipid-lowering drugs; pharmaceutical care; pharmacist intervention; statins; RANDOMIZED CONTROLLED-TRIAL; CORONARY-HEART-DISEASE; STATIN THERAPY; COMMUNITY PHARMACIES; MYOCARDIAL-INFARCTION; ELDERLY PATIENTS; BLOOD-PRESSURE; PERSISTENCE; CHOLESTEROL; PROGRAM;
D O I
10.1177/1060028013501146
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Bachground: Lipid-lowering drugs are effective preventive medication for patients at risk of cardiovascular complications. However, medication adherence is suboptimal, thereby decreasing therapy effectiveness. Pharmaceutical care interventions may increase therapy adherence. Objective: To assess the effect of a proactive pharmaceutical care intervention program, Medication Monitoring and Optimization (MeMO), on therapy discontinuation and adherence with lipid-lowering drugs as well as patients' satisfaction with the intervention program. Methods: This prospective intervention study included 1002 patients initiating lipid-lowering drug therapy from 9 Dutch community pharmacies. In the intervention group (n = 500), the MeMO program was used, comprising continuous monitoring of patients' adherence to lipid-lowering drugs and personal counseling with nonadherent patients. The intervention group was compared with a historical reference group (n = 502) receiving usual care. Outcomes were therapy discontinuation and adherence. Results: Discontinuation rates with lipid lowering drugs in the first year after drug initiation were 13.6% for the intervention group and 25.9% in the usual care group; continued but non-adherent use was 3.2% and 7.6% in these groups. Patients in the MeMO program had a decreased risk to discontinue medication of 51% (95% confidence interval: 34%-63%). Results were not affected by potential confounders. Patient satisfaction with MeMO was very high; one quarter of patients mentioned that they only received information about their medication from their pharmacy. Conclusions: Improving adherence to lipid lowering drugs can be achieved by a proactive pharmaceutical care program. Pharmacists can contribute to optimal use of chronic medication, which is likely to reduce healthcare costs.
引用
收藏
页码:1448 / 1456
页数:9
相关论文
共 50 条
  • [31] Predictors of adherence with antihypertensive and lipid-lowering therapy
    Chapman, RH
    Benner, JS
    Petrilla, AA
    Tierce, JC
    Collins, SR
    Battleman, DS
    Schwartz, JS
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (10) : 1147 - 1152
  • [32] Medication persistence with lipid-lowering treatment in Slovenia
    Deticek, Andreja
    Kersmanc, Nina Evelina
    Mardetko, Nika
    Kos, Mitja
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (03) : 624 - 625
  • [33] Adherence With Lipid-Lowering, Antihypertensive, and Diabetes Medications
    Davis, James W.
    Fujimoto, Ronald Y.
    Chan, Henry
    Juarez, Deborah T.
    [J]. AMERICAN JOURNAL OF PHARMACY BENEFITS, 2011, 3 (03) : 165 - 171
  • [34] COST-EFFECTIVENESS OF ADHERENCE-IMPROVING INTERVENTIONS FOR ANTIHYPERTENSIVE AND LIPID-LOWERING MEDICATIONS
    Chapman, R. H.
    Kowal, S.
    Cherry, S. B.
    Ferrufino, C. P.
    Roberts, C. S.
    Chen, L.
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2009, 24 : 49 - 49
  • [35] INTERVENTIONS TO IMPROVE MEDICATION ADHERENCE IN PATIENTS WITH INFLAMMATORY ARTHRITIS
    Vriezekolk, J. E.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 39 - 39
  • [36] Does adherence to lipid-lowering medications predict CPAP adherence?
    Platt, A.
    Field, S. H.
    Zhen, C.
    Christie, J. D.
    Roche, D.
    Gupta, R.
    Asch, D. A.
    Kuna, S. T.
    [J]. SLEEP, 2008, 31 : A150 - A151
  • [37] VASCULAR FUNCTION IN THE FOREARM OF HYPERCHOLESTEROLEMIC PATIENTS OFF AND ON LIPID-LOWERING MEDICATION
    STROES, ESG
    KOOMANS, HA
    DEBRUIN, TWA
    RABELINK, TJ
    [J]. LANCET, 1995, 346 (8973): : 467 - 471
  • [38] PATTERNS OF LIPID-LOWERING MEDICATION USE BY PATIENTS VISITING US PHYSICIANS
    STAFFORD, RS
    BLUMENTHAL, D
    [J]. CIRCULATION, 1995, 92 (08) : 3409 - 3409
  • [39] Lipid-lowering therapy and percutaneous coronary interventions
    Koskinas, Konstantinos C.
    Mach, Francois
    Raber, Lorenz
    [J]. EUROINTERVENTION, 2021, 16 (17) : 1389 - 1403
  • [40] Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease
    Chan, Joyce
    Rajalingam, Tharshan
    Fossella, Jonathon
    Zhou, Hui
    Eisenberg, Naomi
    Roche-Nagle, Graham
    [J]. ANNALS OF VASCULAR SURGERY, 2020, 69 : 197 - 205